News Column

Findings on Nanoparticles Detailed by Investigators at Xiamen University (Methotrexate-Loaded PEGylated Chitosan Nanoparticles: Synthesis,...

August 13, 2014



Findings on Nanoparticles Detailed by Investigators at Xiamen University (Methotrexate-Loaded PEGylated Chitosan Nanoparticles: Synthesis, Characterization, and in Vitro and in Vivo Antitumoral Activity)

By a News Reporter-Staff News Editor at Biotech Week -- A new study on Nanoparticles is now available. According to news reporting from Fujian, People's Republic of China, by NewsRx journalists, research stated, "Cancer nanotherapeutics are rapidly progressing and being implemented to solve several limitations of conventional drug delivery systems. In this paper, we report a novel strategy of preparing methotrexate (MTX) nanopartides based on chitosan (CS) and methoxypoly(ethylene glycol) (mPEG) used as nanocarriers to enhance their targeting and prolong blood circulation."

The news correspondents obtained a quote from the research from Xiamen University, "MTX and mPEG-conjugated CS nanopartides (NPs) were prepared and evaluated for their targeting efficiency and toxicity in vitro and in vivo. The MTX-mPEG-CS NP size determined by dynamic light scattering was 213 +/- 2.0 nm with a narrow particle size distribution, and its loading content (LC %) and encapsulation efficiency (EE) were 44.19 +/- 0.64% and 87.65 +/- 0.79%, respectively. In vitro release behavior of MTX was investigated. In vivo optical imaging in mice proved that MTX was released from particles subsequently and targeted to tumor tissue, showing significantly prolonged retention and specific selectivity. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay obviously indicated that the higher inhibition efficiency of MTX-mPEG-CS NPs meant that much more MTX was transferred into the tumor cells. A significant right-shift in the flow cytometry (FCM) assay demonstrated that MTX-loaded nanopartides were far superior to a pure drug in the inhibition of growth and proliferation of Hela cells."

According to the news reporters, the research concluded: "These results suggest that MTX mPEG CS NPs could be a promising targeting anticancer chemotherapeutic agent, especially for cervical carcinoma."

For more information on this research see: Methotrexate-Loaded PEGylated Chitosan Nanoparticles: Synthesis, Characterization, and in Vitro and in Vivo Antitumoral Activity. Molecular Pharmaceutics, 2014;11(7):2213-2223. Molecular Pharmaceutics can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)

Our news journalists report that additional information may be obtained by contacting J. Chen, Xiamen University, Biomed Engn Res Center, Coll Mat, Xiamen 361005, Fujian, People's Republic of China. Additional authors for this research include L.Q. Huang, H.X. Lai, C.H. Lu, M. Fang, Q.Q. Zhang and X.T. Luo (see also Nanoparticles).

Keywords for this news article include: Asia, Fujian, Nanotechnology, Emerging Technologies, People's Republic of China

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters